Immuneering Corporation Class A Common Stock (IMRX) Stock
NASDAQ · IMRX
Key stats
- Market cap
- $245.45M
- Price / Earnings ratio
- -3.7x
- EPS (TTM)
- -$0.92
- Volume
- Loading
- 52-week high
- $8.48
- 52-week low
- $3.35
Source: third-party data provider, as of November 13, 2026
Compare with IMRX
Recent news

Zacks Investment Research
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know
IMRXJuly 15, 2026
Zacks Investment Research
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know
IMRX

Zacks Investment Research
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
IMRXJune 12, 2026
Zacks Investment Research
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
IMRX

Stocktwits
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff?
IMRXJune 1, 2026
Stocktwits
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff?
IMRX

24/7 Wall Street
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
IMRXMarch 9, 2026
24/7 Wall Street
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
IMRX
Technical indicators
- RSI 14
- 49.27
- MACD 12/26/9
- -0.08
- EMA 9 of MACD
- -0.12
- MACD histogram
- 0.03
- SMA 50
- $4.05
- Price below SMA 50
- EMA 50
- $4.01
- Price below EMA 50
- SMA 200
- $4.76
- Price below SMA 200
- EMA 200
- $4.78
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
2M2M8236650
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
278M184M92M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-56.0M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Zacks Investment Research
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know
IMRXJuly 15, 2026
Zacks Investment Research
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know
IMRX

Zacks Investment Research
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
IMRXJune 12, 2026
Zacks Investment Research
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
IMRX

Stocktwits
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff?
IMRXJune 1, 2026
Stocktwits
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff?
IMRX

24/7 Wall Street
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
IMRXMarch 9, 2026
24/7 Wall Street
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
IMRX

Stocktwits
IMRX Stock Closed Over 20% Higher Today: Here’s Why
IMRXJanuary 8, 2026
Stocktwits
IMRX Stock Closed Over 20% Higher Today: Here’s Why
IMRX

Zacks Investment Research
All You Need to Know About Immuneering (IMRX) Rating Upgrade to Buy
IMRXDecember 29, 2025
Zacks Investment Research
All You Need to Know About Immuneering (IMRX) Rating Upgrade to Buy
IMRX

Zacks Investment Research
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
IMRXNovember 10, 2025
Zacks Investment Research
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
IMRX

24/7 Wall Street
These Are the Five Best and Worst Performing Small-cap Stocks in September 2022
IMRXOctober 22, 2022
24/7 Wall Street
These Are the Five Best and Worst Performing Small-cap Stocks in September 2022
IMRX
About Immuneering Corporation Class A Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees57
CEODr. Benjamin J. Zeskind M.B.A., Ph.D.
IPO DateJul 28, 2021
HeadquartersCambridge, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Benjamin J. Zeskind M.B.A., Ph.D. | Co-Founder, President, CEO & Director | 1983 |
| Mr. Andrew W. Gengos | CFO & Treasurer | 1964 |
| Mr. Robert J. Carpenter M.B.A., M.S. | Co-Founder & Chair Emeritus | 1946 |
| Dr. Brett M. Hall Ph.D. | Chief Scientific Officer | 1969 |
| Mr. Michael D. Bookman J.D. | Chief Legal Officer & Secretary | 1987 |
| Ms. Paula George CPA | Senior Director of Accounting & Operations and Assistant Corporate Controller | — |
| Ms. Mallory Morales CPA | Senior VP of Finance, Chief Accounting Officer & Assistant Treasurer | 1983 |
| Ms. Jyoti Joshi | Director of Quality Systems & Compliance | — |
| Mr. David Caouette | Vice President of Corporate Communications | — |
| Ms. Leah R. Neufeld | Chief People Officer | 1972 |
Fundamentals
Valuation
Price-to-book value1.48
Profitability
Return on Equity-34.00%
Return on Assets-32.00%
EBITDA$-65.77M
Trading
Average volume770,610
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 49.27
- MACD 12/26/9
- -0.08
- EMA 9 of MACD
- -0.12
- MACD histogram
- 0.03
- SMA 50
- $4.05
- Price below SMA 50
- EMA 50
- $4.01
- Price below EMA 50
- SMA 200
- $4.76
- Price below SMA 200
- EMA 200
- $4.78
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -17.7 | -19.6 | ||||||||||
| 2022 | -41.1 | -27.6 | -7.8 | -33.2 | -17.0 | +36.3 | +30.4 | -13.8 | +106.0 | -7.4 | -53.5 | -24.9 |
| 2023 | +4.5 | +17.3 | +90.4 | +18.8 | -25.8 | +7.6 | +4.4 | -15.3 | -14.7 | -0.7 | +1.2 | -11.1 |
| 2024 | -19.8 | +7.8 | -53.0 | -48.4 | -9.2 | -7.2 | -3.4 | -17.8 | +105.8 | -19.8 | +11.8 | +4.8 |
| 2025 | -12.2 | -12.2 | +2.7 | -20.7 | +32.6 | +80.2 | +0.0 | +70.6 | +16.9 | +8.0 | +16.8 | -7.2 |
| 2026 | -30.1 | +3.5 | +5.4 | -1.7 | +7.4 | +10.9 | -18.2 | +19.7 | -15.5 | -6.9 | +10.3 |
Compare stocks
Market cap
$245.45M
-
-
-
Price / Earnings ratio
-3.70
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
770,610
-
-
-
Earnings per share
$-0.92
-
-
-



